Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes

NCT01647542 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

393

Enrollment

INDUSTRY

Sponsor class

Stopped Due to potential concerns about liver safety (See Detailed Description)

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: TAK-875
DRUG: TAK-875 Placebo

Sponsor

Takeda